Selected publications from journals including the Lancet, Lancet Oncology, Journal of Clinical Oncology, European Urology, NEJM Evidence, Nature Reviews Urology, NPJ Digital Medicine, and the International Journal of Radiation Oncology, Biology, Physics. Click any paper to view it on PubMed. You can also browse the full list on Google Scholar or PubMed Bibliography.
My research program centers on improving how we diagnose, treat, and live with prostate cancer — and on broader questions in radiation science that touch every cancer patient. Below are the six themes that shape most of my work.
Personalizing treatment selection across surgery, radiation, brachytherapy, hormone therapy, and combinations. Trials, meta-analyses, and outcomes research in localized, recurrent, and metastatic disease.
Multimodal deep learning for prostate cancer risk stratification, treatment selection, and trial design. Validated on NRG Oncology phase III randomized trial datasets.
Clinical outcomes, dose optimization, and safety of brachytherapy — including in difficult populations such as inflammatory bowel disease and prior pelvic radiation.
First quantification of greenhouse gas emissions from radiation therapy, published in Lancet Oncology. Ongoing work on hypofractionation, telehealth, and the carbon footprint of cancer care.
Reviews and clinical research from training at the National Institute of Radiological Sciences in Japan. Comparative studies of carbon ions, protons, and conventional radiation across disease sites.
International collaboration on radiotherapy access, hypofractionation adoption, travel distance to care, and cancer care delivery in resource-limited and conflict-affected settings.
Clinical research and trials on prostate cancer treatment, recurrence, hormonal therapy, brachytherapy, stereotactic radiation, and outcomes.
Marqueen KE, Corrigan KL, Prajapati S, Kudchadker RJ, Manzar G, Cha E, Mok H, Tang C, Hassanzadeh C, Mohamad O, Frank SJ. Assessment of brachytherapy-induced prostate edema on postimplant dosimetric analysis in patients treated with MARS. Brachytherapy. 2026.
Kishan AU, Sun Y, Parker CC, et al, Mohamad O, et al. Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis. Lancet. 2026;407(10533):1059-1071.
Hassanzadeh C, Kuban D, et al, Mohamad O, et al. Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III RCT. J Clin Oncol. 2025.
Roach M, Zhang J, Mohamad O, et al. Assessing Algorithmic Fairness With a Multimodal AI Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials. JCO Clin Cancer Inform. 2025;9:e2400284.
Armstrong AJ, Liu VYT, et al, Mohamad O, et al. Development and Validation of an AI Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer. J Clin Oncol. 2025.
Hassanzadeh C, Mohamad O, et al. Early outcomes following local salvage with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrences. Brachytherapy. 2025;24(2):231-237.
Mohamad O, Kouzi ZE, Kouzy R, et al. Safety and early outcomes of proton therapy and low-dose rate brachytherapy boost for patients with prostate cancer. Brachytherapy. 2025;24(2):301-309.
Mohamad O, Mose L, Ahmadsei M, et al. Salvage Radiotherapy Following Nonradiotherapy Ablative Techniques for Primary Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2025.
Mohamad O, Li YR, Feng F, et al. Delayed definitive management of localized prostate cancer: what do we know? Prostate Cancer Prostatic Dis. 2024.
Roy S, Malone S, et al, Mohamad O, et al. Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Secondary Analysis of SPARTAN. JAMA Netw Open. 2024;7(10):e2439434.
Semwal H, Ladbury C, Sabbagh A, Mohamad O, et al. Machine learning and explainable AI to predict pathologic stage in men with localized prostate cancer. Prostate. 2024.
Tward JD, Huang HC, Esteva A, Mohamad O, et al. Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology. JCO Precis Oncol. 2024;8:e2400145.
Roy S, Saad F, Sun Y, et al, Mohamad O, et al. Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of SPARTAN. Eur J Cancer. 2024;211:114197.
Scholey J, Nano T, Singhrao K, Mohamad O, Singer L, et al. Linac- and CyberKnife-based MRI-only treatment planning of prostate SBRT using an optimized synthetic CT calibration curve. J Appl Clin Med Phys. 2024;25(9):e14411.
Ross AE, Zhang J, Huang HC, et al, Mohamad O, et al. External Validation of a Digital Pathology-based Multimodal AI Architecture in the NRG/RTOG 9902 Phase 3 Trial. Eur Urol Oncol. 2024.
Roy S, Saad F, Malone S, et al, Mohamad O, et al. Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: Secondary Analysis of TITAN. Eur Urol. 2024;85(4):398-400.
Mohamad O, Nicosia L, Mathier E, et al. Focal brachytherapy as definitive treatment for localized prostate cancer: A systematic review and meta-analysis. Brachytherapy. 2024;23(3):309-320.
Thomas H, Chen JJ, Shaheen H, et al, Mohamad O. Safety of high-dose rate (HDR) brachytherapy for patients with prostate cancer and inflammatory bowel disease: a case series. J Contemp Brachytherapy. 2024.
Thomas H, Chen JJ, Abdul-Baki H, et al, Mohamad O. Safety of high-dose rate (HDR) brachytherapy for patients with prostate cancer and history of prior chemoradiation for rectal cancer: a case series. Brachytherapy. 2023.
Mohamad O, Zamboglou C, Zilli T, et al. Safety of Ultrahypofractionated Pelvic Nodal Irradiation in the Definitive Management of Prostate Cancer: Systematic Review and Meta-analysis. Int J Radiat Oncol Biol Phys. 2024;118(4):998-1010.
Shaheen H, Roach M, Salans M, Mohamad O, Coleman P, Ahmed S. Age 70 ± 5 Years and Cancer Specific Outcomes after Treatment of Localized Prostate Cancer: A Systematic Review. Int J Radiat Oncol Biol Phys. 2024.
Baskin A, Cowan JE, Braun A, Lonergan PE, Mohamad O, et al. Long-term complications and health-related quality of life outcomes after radical prostatectomy with or without subsequent radiation for prostate cancer. Urol Oncol. 2023.
Lonergan PE, Baskin A, Greenberg SA, Mohamad O, et al. The Long-term Incidence and Quality of Life Outcomes Associated With Treatment-Related Toxicities of External Beam Radiotherapy for Prostate Cancer. Urology. 2023.
Sadighian M, Hakam N, et al, Mohamad O, Breyer BN. Radiation-induced Fistulas in Patients With Prior Pelvic Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis. Urology. 2023.
Spratt DE, Tang S, Sun Y, et al, Mohamad O, et al. Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. NEJM Evid. 2023;2(8):EVIDoa2300023.
Sabbagh A, Weiss J, Tawk B, et al, Mohamad O. Hypofractionation adoption in prostate cancer radiotherapy: Results of an international survey. JCO Glob Oncol. 2023.
Sabbagh A, Washington SL 3rd, Tilki D, et al, Mohamad O. Multi-institutional development and external validation of a machine learning model for the prediction of distant metastasis in patients treated by salvage radiotherapy for biochemical failure after radical prostatectomy. Eur Urol Focus. 2023.
Sabbagh A, Washington SL 3rd, Tilki D, et al, Mohamad O. Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer. Eur Urol Oncol. 2023.
Ni L, Chen K, Phuong C, Sabbagh AR, Wong AC, Mohamad O, Hsu IC. Outcomes of salvage high dose-rate brachytherapy with or without pelvic EBRT in patients with palpable local recurrence of prostate cancer after radical prostatectomy. Brachytherapy. 2023.
Tilki D, Chen MH, Wu J, Huland H, Graefen M, Mohamad O, et al. Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol. 2023.
Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, et al. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. Urol Oncol. 2023;41(3):145.e7-145.e15.
Esteva A, Feng J, van der Wal D, et al, Mohamad O. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med. 2022;5(1):71.
Alexander J, Beatty A, Mohamad O, Hsu IJ. Relative Incidence of Emergency Department Visits After Treatment for Prostate Cancer with Radiation Therapy or Radical Prostatectomy. Pract Radiat Oncol. 2022.
Phuong C, Chan JW, Ni L, Wall P, Mohamad O, Wong AC, Hsu IC, Chang AJ. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to HDR brachytherapy or SBRT prostate boost. Radiat Oncol. 2022;17(1):12.
Hannan R, Salamekh S, Desai NB, et al, Mohamad O, et al. Stereotactic Ablative Radiotherapy for High-Risk Prostate Cancer — a Prospective Multi-level MRI-based Dose Escalation Trial. Int J Radiat Oncol Biol Phys. 2021.
Ferdinandus J, Fendler WP, Farolfi A, et al, Mohamad O, et al. PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study. J Nucl Med. 2021.
van der Wal D, Jhun I, Laklouk I, et al, Mohamad O, et al. Biological data annotation via a human-augmenting AI-based labeling system. NPJ Digit Med. 2021;4(1):145.
Tilki D, Chen MH, Wu J, et al, Mohamad O, et al. Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol. 2021;39(20):2284-2293.
Jairath NK, Dal Pra A, Vince R, et al, Mohamad O, et al. A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Eur Urol. 2021;79(3):374-383.
Levin-Epstein RG, Jiang NY, Wang X, et al, Mohamad O, et al. Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of PSA kinetics and biochemical control. Radiother Oncol. 2020;154:207-213.
Mohamad O, Tabuchi T, et al. Risk of Subsequent Primary Cancers after Carbon Ion Radiotherapy, Photon Radiotherapy, or Surgery for Localised Prostate Cancer: A Propensity Score-weighted, Retrospective Cohort Study. Lancet Oncol. 2019;20(5):674-685.
Shelan M, Achard V, Appiagyei F, et al, Mohamad O, et al. Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials. Prostate Cancer Prostatic Dis. 2024;27(3):422-431.
Mohamad O*, Sabbagh A*, Lichter KE, Hope TA. Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET. Cancers (Basel). 2022;14(24):6194. (co-first authors)
Ni HM, Kouzy R, Sabbagh A, et al, Mohamad O. The state of the art in artificial intelligence and digital pathology in prostate cancer. Nat Rev Urol. 2025.
Rooney MK, El Kouzi Z, Kouzy R, Mohamad O, Hoffman KE. High-Risk Localized Prostate Cancer: Why Combination Hormone Therapy and Radiotherapy is the Optimal Treatment Strategy for Most Men. Semin Radiat Oncol. 2025;35(3):393-401.
Zamboglou C, Doncker W, Christoforou AT, et al, Mohamad O, et al. Digital pathology biomarkers for guiding radiotherapy-based treatment concepts in prostate cancer — a systematic review and expert consensus. Radiother Oncol. 2025;210:111039.
Belabaci Z, Mose L, et al, Mohamad O, et al. Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review. Pharmaceuticals (Basel). 2025.
Research on renal cell carcinoma, bladder cancer, and testicular cancer — including stereotactic ablative radiotherapy, immunotherapy combinations, and MR-guided treatment.
Mose L, Maitre P, Eberz P, et al, Mohamad O, et al. Treatment approaches for non-metastatic small cell bladder cancer: a meta-analysis. Clin Transl Radiat Oncol. 2025;55:101032.
Carriere P, Alhalabi O, Gao J, Mohamad O, et al. Metastasis-directed radiotherapy for oligometastatic urothelial carcinoma of the bladder and upper tract. Bladder Cancer. 2026.
Zhao Y, Cozma A, Ding Y, et al, Mohamad O, et al. Upper Urinary Tract Stereotactic Body Radiotherapy Using a 1.5 Tesla MR-Guided Linear Accelerator: Workflow and Physics Considerations. Cancers (Basel). 2024;16(23):3987.
Carriere P, Alhalabi O, Gao J, Mohamad O, et al. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clin Transl Radiat Oncol. 2024;49:100866.
Terbuch A, Posch F, Bauernhofer T, et al, Mohamad O, et al. Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022.
Hannan R, Mohamad O, Diaz de Leon A, et al. Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2021.
Margulis V, Freifeld Y, et al, Mohamad O, et al. Neoadjuvant SAbR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus — Safety Lead-in Results of a Phase II Trial. Int J Radiat Oncol Biol Phys. 2021.
Mohamad O*, Schoenhals JE*, Christie A, et al. Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma. Adv Radiat Oncol. 2021;6(5):100692. (co-first authors)
Zhang Y, et al, Mohamad O, et al. Stereotactic Ablative Radiotherapy used to Defer Systemic therapy in Oligometastatic Renal Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2019;105(2):367-375.
Clinical experiences and reviews on carbon ion radiotherapy and particle therapy from training at the National Institute of Radiological Sciences in Japan.
Mohamad O, Imai R, et al. Carbon Ion Radiotherapy for Inoperable Pediatric Osteosarcoma. Oncotarget. 2018;9(33):22976-22985.
Mohamad O, Durante M. Clinical indications of Carbon Ion Radiotherapy. Clin Oncol (R Coll Radiol). 2018;30(5):317-329.
Mohamad O, Makishima H, Kamada T. Evolution of Carbon Ion Radiotherapy at the National Institute of Radiological Sciences in Japan. Cancers (Basel). 2018;10(3).
Mohamad O, Sishc BJ, Saha J, et al. Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair. Cancers (Basel). 2017;9(6).
Makishima H, Yasuda S, Isozaki Y, et al, Mohamad O, et al. Single Fraction Carbon Ion Radiotherapy for Liver Metastasis from Colorectal Cancer. Cancer Sci. 2019;110(1):303-309.
Mohamad O, et al. Key considerations when reviewing subsequent primary cancers following radiotherapy — Author's reply. Lancet Oncology. 2019;20(6):e202.
Research on the environmental impact of radiation oncology and the climate footprint of healthcare — including the first published quantification of radiotherapy emissions.
Lichter KE, Asaro A, Qureshi MM, et al, Mohamad O. The climate and health impact of U.S. radiation therapy: estimating greenhouse gas emissions, DALYs, and potential of hypofractionation. Radiother Oncol. 2026;214:111161.
Baniel CC, Lichter KE, Frick MA, et al, Mohamad O, et al. The NorCal brachytherapy waste audit: A simple, validated toolkit for clinician led waste reduction. Brachytherapy. 2025.
Lichter KE, Charbonneau K, Lewy JR, et al, Mohamad O. Quantification of the environmental impact of radiotherapy and associated secondary human health effects: a multi-institutional retrospective analysis and simulation. Lancet Oncol. 2024;25(6):790-801.
Lichter KE, Baniel CC, Do I, et al, Mohamad O. Effects of Wildfire Events on California Radiation Oncology Clinics and Patients. Adv Radiat Oncol. 2024;9(3):101395.
Lichter KE, Sabbagh A, Demeulenaere S, et al, Mohamad O. Reducing the Environmental Impact of Healthcare Conferences: A Study of Emissions and Practical Solutions. JCO Glob Oncol. 2024;10:e2300209.
Smolen KA, Luu J, Braunstein S, Prionas N, Mohamad O, et al. Shifting gears to green: A pilot study on decarbonizing patient transport. J Climate Change Health. 2024.
Lichter KE, Charbonneau K, Sabbagh A, et al, Mohamad O. Evaluating the Environmental Impact of Radiotherapy Using Life Cycle Assessments: A Critical Review. Int J Radiat Oncol Biol Phys. 2023.
Lichter KE, Anderson J, Sim AJ, et al, Mohamad O. Transitioning to Environmentally Sustainable, Climate-Smart Radiation Oncology Care. Int J Radiat Oncol Biol Phys. 2022;113(5):915-924.
Lichter KE, Baniel CC, Anderson J, et al, Mohamad O. Environmentally sustainable brachytherapy care. Brachytherapy. 2022.
Lichter KE, Drew T, Demeulenaere S, et al, Mohamad O, et al. Environmental Outcomes Associated With Transition From In-Person to a Virtual Oncology Conference During the COVID-19 Pandemic. JAMA Oncol. 2022.
Research on breast cancer, pediatric malignancies, brain tumors, sarcoma, and immuno-oncology — work from training and faculty years.
Attar-Olyaee R, Kouzy R, Rooney MK, et al, Mohamad O. Cancer Risk Concerns and Communication Gaps Regarding GLP-1 Medications. JAMA Netw Open. 2025;8(7):e2521878.
Lichter KE, Larson B, Pagadala M, Mohamad O, Nogueira L. Impact of declared wildfire disasters on survival of lung cancer patients undergoing radiation. Cancer Causes Control. 2025.
Mushonga M, Weiss J, Liu ZA, et al, Mohamad O, et al. Hypofractionation in Breast Cancer Radiotherapy Across World Bank Income Groups: International Survey. JCO Glob Oncol. 2023;9:e2200127.
Mohamad O, Wardak Z, Bowers DC, et al. Margin-Free Fractionated Stereotactic Radiation Therapy for Pediatric Brain Tumors. Pract Radiat Oncol. 2020;10(6):e485-e494.
Lin M, Yang M, Dougherty J, et al, Mohamad O, et al. Radiation Therapy for Pediatric Brain Tumors using Robotic Radiation Delivery System and Intensity Modulated Proton Therapy. Pract Radiat Oncol. 2020;10(3):e173-e182.
El Ahmadieh T, Aoun S, Plitt A, Mohamad O, et al. Fractionated Stereotactic Radiotherapy for Pediatric Oculomotor Schwannoma. World Neurosurg. 2019;129:487-496.
Rahimi A, Mohamad O, Kim N, et al. Novel Hyaluronan Formulation for Preventing Acute Skin Reactions in Breast during Radiotherapy: A Randomized Clinical Trial. Support Care Cancer. 2020;28(3):1481-1489.
Mkanna A, Mohamad O, et al. Predictors of Cardiac Sparing in Deep Inspiration Breath-hold for Patients with Left Sided Breast Cancer. Front Oncol. 2018.
Mohamad O, Diaz De Leon A, et al. Safety and Efficacy of Concurrent Immune Checkpoint Inhibitors and Hypofractionated Body Radiotherapy. Oncoimmunology. 2018;7(7).
Mohamad O, Shiao J, et al. Deep Inspiration Breath-hold for Left-sided Breast Cancer Patients with Unfavorable Cardiac Anatomy Requiring Internal Mammary Nodal Irradiation. Pract Radiat Oncol. 2017;7(6):e361-e367.
Chen D, Song M, Mohamad O, et al. Inhibition of Na+/K+-ATPase Induces Hybrid Cell Death and Enhanced Sensitivity to Chemotherapy in Human Glioblastoma Cells. BMC Cancer. 2014;14:716.
Research on radiation oncology training, fellowship outcomes, hypofractionation adoption worldwide, and patient access to care.
Kouzy R, Ibrahim I, Nemr P, et al, Mohamad O, et al. Evaluation of AI chatbot responses to brachytherapy frequently asked questions. Brachytherapy. 2026;25(2):275-282.
Silverwood SM, Waeldner K, Demeulenaere SK, et al, Mohamad O. The Relationship Between Travel Distance for Treatment and Outcomes in Patients Undergoing Radiation Therapy: A Systematic Review. Adv Radiat Oncol. 2024;9(12):101652.
Silverwood S, Lichter K, Conway A, et al, Mohamad O, et al. Distance Traveled by Patients Globally to Access Radiotherapy: A Systematic Review. Int J Radiat Oncol Biol Phys. 2023.
Chowdhary M, O'Bryant S, Peters GW, Vapiwala N, Mohamad O, Royce TJ. United States Radiation Oncology Fellowship Growth From 2010 to 2020. Int J Radiat Oncol Biol Phys. 2021;111(3):622-626.
Rodin D, Tawk B, Mohamad O, et al. Hypofractionated radiotherapy in the real-world setting: An international ESTRO-GIRO survey. Radiother Oncol. 2021.
Doke K, Mohamad O, et al. Fellowship Training Programs in Radiation Oncology: A Snapshot from 2005-2017. Int J Radiat Oncol Biol Phys. 2019;104(4):765-772.
Mohamad O, Doke K, et al. A Fellow's Fate: Employment Outcomes of Radiation Oncology Fellowship Graduates in the United States. Int J Radiat Oncol Biol Phys. 2018;102(1):16-17.
Mohamad O, Meyer JJ. Recent Trends in Radiation Oncology Fellowship Training in the United States. Int J Radiat Oncol Biol Phys. 2017;99(3):539-540.
Chowdhary M, O'Bryant S, Vapiwala N, Mohamad O, Royce TJ. In Reply to Chowdhry. Int J Radiat Oncol Biol Phys. 2021;111(4):1093.
Doctoral research at Emory University on stem cells, regenerative neuroscience, and stroke recovery — including induced pluripotent stem cell differentiation and stroke models.
Song M, Yu SP, Mohamad O, et al. Optogenetic Stimulation of Glutamatergic Activity in the Striatum Enhances Neurogenesis in the Subventricular Zone of Normal and Stroke Mice. Neurobiol Dis. 2017;98:9-24.
Mohamad O, Song M, Yu SP, Wei L. Efficient Neuronal Differentiation of Mouse ES and iPS Cells Using a Rotary Cell Culture Protocol. Differentiation. 2013;86(4-5):149-58.
Sun J, Wei S, Hall CL, Dix TA, Mohamad O, et al. Acute and Delayed Protective Effects of Pharmacologically Induced Hypothermia in an Intracerebral Hemorrhage Stroke Model in Mice. Neuroscience. 2013;252:489-500.
Song M, Mohamad O, et al. Restoration of Intracortical and Thalamocortical Circuits after Transplantation of Bone Marrow Mesenchymal Stem Cells into the Ischemic Brain of Mice. Cell Transplant. 2013;22(11):2001-15.
Mingke S, Mohamad O, Chen D, Yu SP. Coordinated Development of Voltage-gated Na+ and K+ Currents Regulates Functional Maturation of Pyramidal-like Neurons Derived from Human iPS Cells. Stem Cells Dev. 2013;22(10):1551-63.
Drury-Stewart D, Song M, Mohamad O, et al. Highly Efficient Differentiation of Neural Precursors from Human Embryonic Stem Cells and Benefits of Transplantation after Ischemic Stroke in Mice. Stem Cell Res Ther. 2013;4(4):93.
Mohamad O, Drury-Stewart D, et al. Vector-Free and Transgene-Free Human iPS Cells Differentiate into Functional Neurons and Enhance Functional Recovery after Ischemic Stroke in Mice. PLoS ONE. 2013;8(5):e64160.
Mohamad O, Song M, Wei L, Yu SP. Regulatory Roles of the NMDA Receptor GluN3A Subunit in Locomotion, Pain Perception, and Cognitive Functions in adult mice. J Physiol. 2013;591(1):149-68.
Choi KE, Hall CL, Sun JM, Wei L, Mohamad O, et al. A Novel Stroke Therapy of Pharmacologically Induced Hypothermia after Focal Cerebral Ischemia in Mice. FASEB J. 2012;26(7):2799-810.
Li J, Li Z, Yu SP, Mohamad O, Wei L. N-methyl-D-aspartate Receptor Subtype 3A Promotes Apoptosis in Developing Mouse Brain Exposed to Hyperoxia. Neural Regeneration Research. 2012;7(4):273-7.
Majumder A, Banerjee S, Harrill JA, Machacek DW, Mohamad O, et al. Neurotrophic Effects of Leukemia Inhibitory Factors on Neural Cells Derived from Human Embryonic Stem Cells. Stem Cells. 2012;30(11):2387-99.
Mohamad O, Chen D, Zhang L, et al. Erythropoietin Reduces Cell Death and Hyperalgesia Induced by Peripheral Inflammatory Pain in Neonatal Rats. Mol Pain. 2011;7(1):51.
Drury-Stewart D, Song M, Mohamad O, Yu SP, Wei L. Small Molecule Promoted Adherent and Feeder Free Differentiation of Functional Neurons from Human Embryonic and Induced Pluripotent Stem Cells. J Stem Cells. 2011;6(1):1-7.
Li Y, Yu SP, Mohamad O, Genetta T, Wei L. Sublethal Transient Global Ischemia Stimulates Migration of Neuroblasts and Neurogenesis in Mice. Translational Stroke Research. 2010;1(3):184-196.
Wei L, Wei ZZ, Jiang MQ, Mohamad O, Yu SP. Stem Cell Transplantation Therapy for Multifaceted Therapeutic Benefits after Stroke. Prog Neurobiol. 2017;98:9-24. (Review)
Authored chapters in medical textbooks and reference volumes on radiation oncology, stereotactic radiosurgery, and particle therapy.
Shaaban SG, Ebner D, Mohamad O. Particle Therapy and the Immune System. In: Malouff T, Trifiletti D, eds. Principles and Practice of Particle Therapy. Wiley Publishing; 2022.
Mohamad O, Hannan R, Timmerman R. Stereotactic Ablative Radiotherapy for Renal Cell Carcinoma. In: Trifiletti DM, et al, eds. Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy; 2019.
Mohamad O, Folkert M. Soft Tissue Sarcoma (Ch. 41). In: Chao C, Perez C, Wang T, eds. Radiation Oncology Management Decisions, 4th ed.; 2018.
Mohamad O, Folkert M. Primary Bone Tumors, including Ewing's Sarcoma (Ch. 40). In: Chao C, Perez C, Wang T, eds. Radiation Oncology Management Decisions, 4th ed.; 2018.
Hall CL, Mohamad O, Yu SP, Wei L. Physiologic Methods in Stroke Research. In: Chen J, Xu X, Xu Z, Zhang J, eds. Animal Models of Acute Neurological Injury II. Springer; 2012.
Woodbury A, Mohamad O, Yu SP, Wei L. Inflammation in Ischemic Stroke: Mechanisms, Diagnosis, and Management. In: Ischemic Stroke: Symptoms, Prevention and Recovery. 2012.
Invited editorials, perspective pieces, and commentary on prostate cancer management, radiation oncology, and global health.
Mohamad O, Rooney MK, Hoffman KE. Beyond Salvage: Systemic Therapies for Prostate Cancer Recurrence After Radical Prostatectomy. ASCO Editorial, ASCO GU 2024.
Mohamad O, Hannan R, Tang C. Is Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma a Disease-Modifying Therapy? ASCO Editorial, ASCO GU 2024.
Mohamad O, Feng F. The Time to Evaluate the Impact of PET PSMAs on Management of Prostate Cancer Is Now. Int J Radiat Oncol Biol Phys. 2022;113(2):254-255.
Mohamad O, Feng F. Treating Localized High-Risk Prostate Cancer: Do All Roads Lead to Rome? Int J Radiat Oncol Biol Phys. 2021;110(3):634-635.
Mohamad O, Roach M. Radiation Delay Is Okay, But Where Is the Evidence? JAMA Oncol. 2021.
Mohamad O, Roach M. Delaying Dilemmas: How coronavirus complicated the management of prostate cancer. Int J Radiat Oncol Biol Phys. 2020.
Mohamad O. Radiation therapy elective in Beirut: A brief insight into the challenges of radiation delivery in Lebanon. Appl Rad Oncol. 2019;8(4):31-33.
Mohamad O. The A-bomb Dome: The Peace Memorial Park in Hiroshima. Int J Radiat Oncol Biol Phys. 2018.
Mohamad O, McFarlane M, Rahimi A. Absence of Physiologic Breast Response to Pregnancy and Lactation after Radiation Therapy. Pract Radiat Oncol. 2016;6(2):e25-6.
Mohamad O, Yu SP. Plenty of Pain in Neonates: The Mission to Find a Treatment for the Complications of Premature Birth. J Pain Relief. 2012.